DoH introduces advanced gene-editing therapy for sickle cell disease and thalassemia
28 Mar 2025 15:34
ABU DHABI (ALETIHAD)The Department of Health – Abu Dhabi (DoH) has announced the introduction of CASGEVY, the first CRISPR/Cas9 gene-editing therapy in the UAE, offering innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).The innovative treatment, provided by Abu Dhabi Stem Cells Center (ADSCC), in coordination with DoH and in collaboration with Vertex Pharmaceuticals, a leading biotechnology company, positions Abu Dhabi as a leading destination for life sciences. The first patient is scheduled to begin the groundbreaking therapy at Yas Clinic Hospital in April of this year.CRISPR/Cas9 gene-editing is an innovative technology that enables precise genome editing to treat certain genetic diseases by targeting and altering specific DNA sequences. CASGEVY is a one-time treatment tailored for each patient by extracting the patient's own hematopoietic stem cells, genetically editing them in the lab, and then re-implanting them into the patient's body to provide long-term positive effects.In line with DoH's commitment to fostering innovation and ensuring the health and safety of patients in the emirate, the department has established regulations and guidelines for the management of gene therapies, according to the highest international standards. The treatment has been included in insurance coverage in accordance with established regulations and standards.Commenting on the innovative treatment, Dr. Noura Khamis Al Ghaithi, Undersecretary, DoH, said: 'The Department of Health – Abu Dhabi remains dedicated to safeguarding the health and well-being of our community while continuously enhancing the quality of care. Our goal is to establish the world's most efficient healthcare system through the adoption of the latest innovations and promising technologies. By harnessing genomic sciences, we aim to develop cutting-edge therapeutic solutions to complex health challenges, solidifying Abu Dhabi's position as a global leader in healthcare, life sciences, and innovation.'For her part, Dr. Maysoon Al Karam, Chief Medical Officer at ADSCC and Yas Clinic, said: "Partnerships with leading biotechnology companies such as Vertex Pharmaceuticals represent a significant milestone in ADSCC's global mission, aligning with the UAE's vision and strategic health priorities. She explained, "Patients with genetic disorders such as thalassemia and sickle cell disease will greatly benefit from this revolutionary treatment, which we aim to offer as one of the first advanced gene therapies in the country. As the UAE's leading cellular research institution and the UAE's first FACT-accredited center, we strive through such partnerships to drive medical innovation, developing treatments for a range of critical diseases, and reinforcing Abu Dhabi's position as a global hub for life sciences, in line with the UAE's leadership vision.Hisham Hagar, Senior Country Manager at Vertex GCC, said: 'We are delighted to partner with the Abu Dhabi Stem Cells Center, the UAE's leading cellular research institution, to bring the world's first CRISPR/Cas9 gene-editing medicine to patients in the UAE. This partnership represents a significant step toward bringing transformative medicines to patients in the UAE for serious diseases like SCD and TDT, ultimately advancing our mission to improve patients' lives in the UAE.'
The Emirates Drug Establishment (EDE) in the UAE, has granted a market authorisation for CASGEVY to treat patients aged 12 years and older who suffer from sickle cell disease with recurrent vaso-occlusive crises, as well as transfusion-dependent thalassemia.
Source: Aletihad - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
4 hours ago
- The National
Emiratis who use several types of tobacco are putting themselves at higher risk, study suggests
A seven-year nationwide study has found more than half of Emirati smokers use at least two forms of tobacco, raising concerns they are putting their health at greater risk as a result. The research – based on information collected from more than 2,500 adult citizens – revealed 47 per cent of those who smoke used one type of combustible tobacco, 35 per cent used two types and 18 per cent used three or more. Based on self-reported data, the new study found that such 'poly tobacco' users on average had higher levels of fats called triglycerides in their blood, which can contribute to an increased risk of stroke, heart attack and heart disease. The research also found that any kind of tobacco use was linked to similar indicators of possible cardiovascular disease, including higher levels in the blood of harmful forms of cholesterol. Dr Sukhant Bagdia, a specialist pulmonologist at Burjeel Hospital in Abu Dhabi, emphasised the dangers posed to health by all forms of tobacco smoking. 'In my practice, I have multiple patients, who use not just cigarettes, but also medwahk, shisha and cigars. 'These are the risk factors for cardiovascular issues, even lung inflammation or bronchitis, or even to a certain extent, they would be also responsible for higher likelihood of cancer in the lungs and other organs. 'Those using multiple forms of smoking would be at a higher risk for cardiovascular and pulmonary disease, more comorbidity illness and other general health related issues. 'None of the smoking forms are safe, they all have their own bad side effects.' Previous research in the UAE has found that medwakh users are more than three times as likely as cigarette smokers to be dependent on tobacco, while medwakh and shisha products have been found to contain larger amounts of metals associated with cancer. Charting Emirati health The findings were gathered between 2016 and 2023 as part of the UAE Healthy Future Study, which has recruited around 15,000 people and will follow many of them over time to assess how lifestyle choices, genetics and environment can impact risk factors for obesity, diabetes and heart disease. The survey was launched in 2016 in a partnership between New York University Abu Dhabi and Tamkeen − which collaborates with leading institutions to deliver social, cultural and educational projects − with the support of the Ministry of Health and Prevention and other health bodies. 'Any tobacco use is associated with potential changes in cardiovascular disease markers. That's the take-home message,' said Andrea Leinberger-Jabari, the first author of the study and the assistant director for tobacco research at New York University Abu Dhabi's Public Health Research Centre. Cardiovascular disease is one of numerous health problems linked to smoking, with others including cancer and respiratory conditions such as emphysema. A 2019 study from the US indicated that the risk of death among cigarette smokers who additionally used other types of tobacco was 'as high as and sometimes higher than those of exclusive cigarette smokers'. Gender gap and global picture Data for the study was supplied by 7,535 Emirati adults, of which 2,550 − 34 per cent − were smokers. The seventh edition of The Tobacco Atlas − a global analysis of smoking – in 2022 found 15.5 per cent of men and 2.5 per cent of women used tobacco. These figures represented the entire UAE population, taking into account both Emiratis and residents, with the Healthy Future Study only surveying citizens. World Health Organisation data from 2022 indicated that 22.3 per cent of the world's adult population uses tobacco. Among Emiratis in the study, there is a huge disparity between the sexes when it comes to smoking, with 50 per cent of UAE national men using some form of combustible tobacco, but just seven per cent of women. The work is part of the International Tobacco Control Policy Evaluation Project, which looks at the impact of tobacco-control policies in more than 30 countries that together are home to more than half the world's population. Published in Nicotine and Tobacco Research, the new paper is titled, Factors associated with single, dual and poly combustible tobacco use among Emirati adults in the United Arab Emirates: The UAE Healthy Future and ITC Survey results (2016 – 2023). Ms Leinberger-Jabari said that the UAE Healthy Future Study would provide particularly useful information for researchers about because, being a longitudinal study, it would collect data from the same individuals over many years. 'It's going to be an incredibly helpful study to keep following these individuals over time and look at how tobacco use behaviours might be changing.' Anti-smoking strategy The work will also mean that the UAE can be compared to other countries that are part of the ITC project and could inform global tobacco policy too, Ms Leinberger-Jabari said. Curbing tobacco and e-cigarette use is a top priority for the UAE, with a key public health strategy implementing a smoke-free environment and increased public awareness of the health risks. In 2017 the UAE brought in a 100 per cent tax on tobacco and tobacco products, meaning that 50 per cent of the total retail price is accounted for by tax.
The National
15 hours ago
- The National
Some microplastics pollute water more than others
Microplastics are one of the biggest threats to global water health, with research piling up to show they are everywhere, from oceans and rivers to the air we breathe. The biggest culprits are synthetic textiles and car tyres. A single washing machine load of acrylic clothes − made from a synthetic material often used as a wool substitute − can release an estimated 730,000 fibres into wastewater, according to Plymouth University. The International Union for Conservation of Nature (IUCN) estimates that man-made fabrics account for thirty-five per cent of all primary microplastics in the ocean. Car tyres, the second-largest source at 28 per cent, shed micro and nano-particles as they erode during driving, contaminating the air, soil and waterways. But the problem is bigger than just fast fashion and transport. Microplastics come from other everyday items, such as cleaning products and road markings, making them nearly impossible to avoid. World Ocean Day June 8 marked World Oceans Day, spotlighting the urgent need to protect our seas. In the UAE, Dr Amna Al Dahak, Minister of Climate Change and Environment, warned that the health of the world's oceans is at serious risk: 'Covering more than 70 per cent of the Earth's surface, our oceans are undeniably essential to human lives and livelihoods,' she said. Abu Dhabi has led the region's fight against plastic pollution, introducing a single-use plastic ban on June 1, 2022. By the end of 2024, the campaign had removed 360 million plastic bags from circulation. Globally, the numbers are staggering. According to the UN Environment Programme, humans have produced 9.2 billion tonnes of plastic since the 1950s — 7 billion tonnes of which is now waste. By 2060, plastic waste could nearly triple to one billion tonnes annually if current trends continue. 'Plastic pollution is one of the gravest environmental threats facing Earth,' said Elisa Tonda at the UNEP. 'But it's a problem we can solve.' The Human Impact Emerging research in animal and human cells suggests microplastics may be linked to cancer, heart disease, and reproductive problems. In the UAE, the urgency hits close to home. 'We eat seafood. That plastic enters our food chain, and it stays in our bodies. It's toxic. This isn't just about the environment — it's about public health,' said Ms Al Mazrouei.
Zawya
16 hours ago
- Zawya
ProvenMed appoints Global Health Strategist Bita Bani as Chief Growth Officer to lead international expansion
Abu Dhabi, UAE – ProvenMed, a pioneering MedTech company transforming continence care and digital home diagnostics, proudly announces the appointment of Bita Bani as its new Chief Growth Officer (CGO). This strategic hire comes at a critical juncture, as ProvenMed experiences a significant spike in international interest following its participation in major healthcare and medtech events across the globe. Bita Bani, a seasoned business development executive with an extensive track record in global health ventures, joins ProvenMed to lead its next phase of international expansion. Countries across South America, Europe, North America, and the GCC have expressed serious interest—making it imperative to transition from momentum to structured growth according to Bita. 'After an incredible response from global markets, it's time to scale up,' said Amine Staali, CEO of ProvenMed. 'Bita's deep experience in building strategic partnerships and leading growth in diverse healthcare environments will be instrumental in maximizing the momentum we've gained. With her leadership, we are ready to translate international interest into sustainable market entry and commercial success.' Bita Bani has successfully guided numerous healthtech companies through growth phases spanning market access, licensing, and commercialization. She is known for aligning ambitious go-to-market strategies with real-world healthcare needs, and for forging high-impact collaborations across public and private sectors. 'I'm thrilled to join ProvenMed at such a pivotal stage,' said Bita Bani. 'This is a company driven by purpose and powered by innovation. With the right strategic framework, I believe we can make these technologies accessible to millions of people who need them most.' As ProvenMed continues to build a robust presence across MENA, Bita Bani's experience is expected to enhance the company's strategic expansion and revenue diversification efforts across Europe, and North America as well. With Bita's leadership, ProvenMed is poised to accelerate global adoption of its groundbreaking solutions, forging new pathways in patient-centric digital health About ProvenMed ProvenMed is a medical technology company developing innovative solutions in continence care and at home digital diagnostics. Its sub-brands include: ActivGo® – A discreet wearable for male urinary incontinence. Livv® – Ai-powered digital home lab and testing kits for home use. Together, they empower users with autonomy, privacy, and real-time health insights, promoting dignity and health access across all populations.
